Cysteine cathepsins and their potential in clinical therapy and biomarker discovery

被引:46
|
作者
Fonovic, Marko [1 ,2 ]
Turk, Boris [1 ,2 ]
机构
[1] Jozef Stefan Inst, Dept Biochem Mol & Struct Biol, SI-1000 Ljubljana, Slovenia
[2] Ctr Excellence Integrated Approaches Chem & Biol, Ljubljana, Slovenia
关键词
Biomarker; Cancer; Cathepsin; Cysteine protease; Proteolysis; ACTIVITY-BASED PROBES; AORTIC-VALVE CALCIFICATION; INHIBITOR CYSTATIN-C; RHEUMATOID-ARTHRITIS; CANCER PROGRESSION; PROGNOSTIC MARKER; BONE-RESORPTION; SYNOVIAL-FLUIDS; S EXPRESSION; HISTONE H3;
D O I
10.1002/prca.201300085
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Since their discovery, cysteine cathepsins were generally considered to be involved mainly in the nonspecific bulk protein degradation that takes place within the lysosomes. However, it has become clear that their proteolytical activity can also influence various specific pathological processes such as cancer, arthritis, and atherosclerosis. Furthermore, their localization was found not to be limited strictly to the lysosomes. In the light of those findings, it is not surprising that cysteine cathepsins are currently considered as highly relevant clinical targets. Moreover, recent development of proteomic-based methods for identification of novel physiological substrates of proteases provides a major opportunity also in the field of cysteine cathepsins. In this review, we will therefore present cysteine cathepsin roles in disease progression and discuss their potential relevance as prognostic and diagnostic biomarkers.
引用
收藏
页码:416 / 426
页数:11
相关论文
共 50 条
  • [21] Alternative splicing as a biomarker and potential target for drug discovery
    Le, Kai-qin
    Prabhakar, Bellur S.
    Hong, Wan-jin
    Li, Liang-cheng
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (10) : 1212 - 1218
  • [22] The Future of Cysteine Cathepsins in Disease Management
    Kramer, Lovro
    Turk, Dusan
    Turk, Boris
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2017, 38 (10) : 873 - 898
  • [23] Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials
    Liu, Cong-Lin
    Guo, Junli
    Zhang, Xian
    Sukhova, Galina K.
    Libby, Peter
    Shi, Guo-Ping
    NATURE REVIEWS CARDIOLOGY, 2018, 15 (06) : 351 - 370
  • [24] Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma
    Cheng, Xingbo
    Ren, Zhishuai
    Liu, Zhendong
    Sun, Xiang
    Qian, Rongjun
    Cao, Chen
    Liu, Binfeng
    Wang, Jialin
    Wang, Hongbo
    Guo, Yuqi
    Gao, Yanzheng
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [25] The Interplay of Glycosaminoglycans and Cysteine Cathepsins in Mucopolysaccharidosis
    David, Alexis
    Chazeirat, Thibault
    Saidi, Ahlame
    Lalmanach, Gilles
    Lecaille, Fabien
    BIOMEDICINES, 2023, 11 (03)
  • [26] Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
    Frizler, Maxim
    Stirnberg, Marit
    Sisay, Mihiret Tekeste
    Guetschow, Michael
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (03) : 294 - 322
  • [27] CE-MS in biomarker discovery, validation, and clinical application
    Mischak, Harald
    Schanstra, Joost P.
    PROTEOMICS CLINICAL APPLICATIONS, 2011, 5 (1-2) : 9 - 23
  • [28] Advances in mass spectrometry-based clinical biomarker discovery
    Crutchfield, Christopher A.
    Thomas, Stefani N.
    Sokoll, Lori J.
    Chan, Daniel W.
    CLINICAL PROTEOMICS, 2016, 13
  • [29] Role for Cysteine Protease Cathepsins in Heart Disease Focus on Biology and Mechanisms With Clinical Implication
    Cheng, Xian Wu
    Shi, Guo-Ping
    Kuzuya, Masafumi
    Sasaki, Takeshi
    Okumura, Kenji
    Murohara, Toyoaki
    CIRCULATION, 2012, 125 (12) : 1551 - 1562
  • [30] Distinct roles for cysteine cathepsins in multistage tumorigenesis
    Gocheva, V.
    Zeng, W.
    Ke, D.
    Klimstra, D.
    Reinheckel, T.
    Peters, C.
    Hanahan, D.
    Joyce, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 41 - 41